Risk identification, epidemiology, prediction and treatment of HCV
In its real-world evaluation of treatment effectiveness and observed incidence and prevalence of HCV in a large, general population, this project will inform future HCV screening efforts and treatment options for those patients with HCV.
Context and Aims
Chronic infection with HCV was historically spread through non-sterile medical practices and continues to be spread through other avenues such as intravenous drug use. With the efficacy of recently available treatments for chronic HCV shown in clinical trials, the effectiveness of these drugs is yet to be demonstrated.
This project involves an examination of the incidence and prevalence of HCV to better understand disease trends, disease progression, and associated costs according to demographic and high-risk groups. Further, it is evaluating the effectiveness of new HCV treatments and patients’ immediate and sustained responsiveness to treatment.
The Clalit Research Institute is establishing an HCV disease registry, collating disease incidence and prevalence rates, as well as examining key sub-groups including comorbidities, country of birth and other socio-demographic characteristics.
The Clalit Research Institute is continuously monitoring the treatment patterns, immediate responsiveness and sustained effectiveness (sustained viral response) of patients receiving new treatment regimens.
Key Findings and/or Potential Impact
This study will identify annual prevalence and incidence rates of HCV in a large general population based on laboratory findings, with early findings indicating generally low rates in the overall population, and higher rates among members who immigrated from the former USSR.
Clalit is the largest early adopter of novel treatment regimens and thus distinctly positioned to conduct real-world effectiveness studies.